

CURRICULUM VITAE

CHEN Bonan

PERSONAL DATA

Full Name: CHEN Bonan
Office Address: 5/F, Cancer Center, Prince of Wales Hospital
Telephone No.: 852-65092144
E-mail Address: chenbonan1994@gmail.com
Webpage (URL): <https://scholar.google.com.hk/citations?user=x8nPN1kAAAAJ&hl>
Web of Science: <https://www.webofscience.com/wos/author/record/GQB-3701-2022>
Scopus: <https://www.scopus.com/authid/detail.uri?authorId=57204266081>
ORCID ID: 0000-0002-2430-7934

EDUCATION

2020-2023 **Ph.D. (Anatomical and Cellular Pathology),**
The Chinese University of Hong Kong, Hong Kong SAR
Thesis: Delineating the driving role of YAP1-SLC39A10 axis in gastric carcinogenesis through potentiating RAS-MAPK pathway to alleviate ER stress
Supervisor: Professor Wei KANG

2017-2020 **Medicine Master (Integrated Traditional Chinese and Western Medicine),**
Guangzhou University of Chinese Medicine, Guangzhou, China
Thesis: Fangchinoline inhibits non-small cell lung cancer metastasis by reversing epithelial-mesenchymal transition and suppressing the cytosolic ROS-related Akt-mTOR signaling pathway
Supervisor: Professor Jianyong XIAO

2012-2017 **Bachelor of Medicine (Traditional Chinese Medicine),**
Guangzhou University of Chinese Medicine, Guangzhou, China

WORKING EXPERIENCE

2023.11-present Postdoctoral Fellowship, Department of Anatomical and Cellular Pathology, CUHK

PROFESSIONAL SOCIETIES

2022-present **Hong Kong Young Scientist Association**, Membership
2022-present **Hong Kong Biotechnology Organization**, Membership
2021-present **United European Gastroenterology**, Young GI Associate

GRANTS (as PI)

- 1 RGC Postdoctoral Fellowship Scheme (PDFS) (RGC Reference No. UGC/GEN/562/3): *Deciphering the Gastric Cancer Microenvironment: Significance of the NF- κ B-YAP1-COL12A1 Axis in Cancer-Associated Fibroblast and Cancer Cell Interactions* [The Research Grants Council of Hong Kong]. Principal Investigator; Duration: 01/08/2024-31/07/2027; Amount: HK\$1,260,270
- 2 National Natural Science Foundation of China (NSFC) (2024, No. 82403017): *Exploring the mechanism by which YAP1 transcriptional regulation of ZIP10 mediates zinc ion influx to alleviate endoplasmic reticulum stress and promote gastric cancer* [PR China]. Principal Investigator; Duration: 01/01/2025-31/12/2027; Amount: RMB300,000

GRANTS (as co-I)

- 1 National Natural Science Foundation of China (NSFC) (2020, No. 82074070): *The effect and molecular mechanism of Fangchinoline in enhancing lung cancer chemotherapy by blocking autophagic flux* [PR China]. Participant; Duration: 01/01/2021-31/12/2024; Amount: RMB550,000.

LIST OF RESEARCH OUTPUTS OR CREATIVE WORKS

Journal publications (Total: 39) (Total citations: **862**; H-index: **18**; Source: **Google Scholar**)

ORCID ID link: <https://orcid.org/0000-0002-2430-7934>

Total publications: **41**; as first (or co-) or corresponding (or co-) author publications: **14**

2024

- 1 **Chen B**, Yu P, Chan WN, Xie F, Zhang Y, Liang L, Leung KT, Lo KW, Yu J, Tse GMK, Kang W, To KF. *Cellular zinc metabolism and zinc signaling: from biological functions to diseases and therapeutic targets*, Signal Transduction and Targeted Therapy, (2024) (IF: 39.3; Ranking 3/285 in BIOCHEMISTRY & MOLECULAR BIOLOGY)
- 2 Liu X, **Chen B (co-first)**, Xie F, Wong KY, Cheung AH, Zhang J, Wu Q, Fang C, Hu J, Wang S, Xu D, Chen J, Wang Y, Wong CC, Chen H, Wu WKK, Yu J, Chan MWY, Tsang CM, Lo KW, Tse GMK, To KF, Kang W. *FOXP4 is a Direct YAP1 Target that Promotes Gastric Cancer Stemness and Drives Metastasis*. Cancer Research, (2024) (IF: 12.5; Ranking 20/322 in ONCOLOGY)
- 3 Lyu Y, Xie F, **Chen B**, Shin WS, Chen W, He Y, Leung KT, Tse GMK, Yu J, To KF, Kang W. *The nerve cells in gastrointestinal cancers: from molecular mechanisms to clinical intervention*. Oncogene, (2024) (IF: 8.0; Ranking 36/285 in BIOCHEMISTRY & MOLECULAR BIOLOGY)
- 4 Guan X, Wang Y, Yu W, Wei Y, Lu Y, Dai E, Dong X, Zhao B, Hu C, Yuan L, Luan X, Miao K, **Chen B**, Cheng XD, Zhang W, Qin JJ. *Blocking Ubiquitin-Specific Protease 7 Induces Ferroptosis in Gastric Cancer via Targeting Stearoyl-CoA Desaturase*. Advanced Science, (2024) (IF: 15.1; Ranking 16/178 in CHEMISTRY, MULTIDISCIPLINARY)

- 5 Zhang Y, Lei Y, Dong Y, Chen S, Sun S, Zhou F, Zhao Z, **Chen B**, Wei L, Chen J, Meng Z. *Emerging roles of RNA ac4C modification and NAT10 in mammalian development and human diseases*. Pharmacology & Therapeutics, (2024) (IF: 12.0; Ranking 8/354 in PHARMACOLOGY & PHARMACY)
- 6 Yong Q, Huang C, **Chen B**, An J, Zheng Y, Zhao L, Peng C, Liu F. *Gentiopicroside improves NASH and liver fibrosis by suppressing TLR4 and NLRP3 signaling pathways*. Biomedicine & Pharmacotherapy, (2024) (IF: 6.9; Ranking 18/189 in MEDICINE, RESEARCH & EXPERIMENTAL)
- 7 Chen G, Ren Q, Zhong Z, Li Q, Huang Z, Zhang C, Yuan H, Feng Z, **Chen B**, Wang N, Feng Y. *Exploring the gut microbiome's role in colorectal cancer: diagnostic and prognostic implications*. Frontiers in Immunology, (2024) (IF: 5.7; Ranking 37/181 in IMMUNOLOGY)

2023

- 8 **Chen B**, Chan WN, Xie F, Mui CW, Liu X, Cheung AHK, Lung RWM, Chow C, Zhang Z, Fang C, Yu P, Shi S, Zhou S, Chen G, Wang Z, Wang S, Ding X, Huang B, Liang L, Dong Y, Wong CC, Wu WKK, Cheng ASL, Wong N, Yu J, Lo KW, Tse GMK, Kang W, To KF. *The molecular classification of cancer-associated fibroblasts on a pan-cancer single-cell transcriptional atlas*, Clinical and Translational Medicine, (2023) (IF: 10.6; Ranking 31/241 in ONCOLOGY)
- 9 **Chen B**, Liu X, Yu P, Xie F, Kwan JSH, Chan WN, Fang C, Zhang J, Cheung AHK, Chow C, Leung GWM, Leung KT, Shi S, Zhang B, Wang S, Xu D, Fu K, Wong CC, Wu WKK, Chan MWY, Tang PMK, Tsang CM, Lo KW, Tse GMK, Yu J, To KF, Kang W. *H. pylori-induced NF- κ B-PIEZO1-YAP1-CTGF axis drives gastric cancer progression and cancer-associated fibroblast-mediated tumour microenvironment remodelling*, Clinical and Translational Medicine, (2023) (IF: 10.6; Ranking 31/241 in ONCOLOGY)
- 10 Zhang J, **Chen B (co-first)**, Wang Y, Liu X, Yan H, Wong KY, Chan AK, Cheung AHK, Chow C, Xu D, Wang S, Huang B, Ling L, Ke H, Wong C, Wu WKK, Cheng ASL, Yu J, Lo KW, To KF, Kang W, *The E2F1–HOXB9/PBX2–CDK6 axis drives gastric tumorigenesis and serves as a therapeutic target in gastric cancer*, Journal of Pathology, (2023) (IF: 7.3; Ranking 45/241 in ONCOLOGY)
- 11 Zhang Y, Lei Y, Dong Y, Chen S, Sun S, Zhou F, Zhao Z, **Chen B**, Wei L, Chen J, Meng Z. *Emerging roles of RNA ac4C modification and NAT10 in mammalian development and human diseases*, Pharmacology & Therapeutics, (2023) (IF: 13.5; Ranking 7/278 in PHARMACOLOGY & PHARMACY)
- 12 Hu S, Luo D, Zhu Q, Pan J, **Chen B**, Furian M, Harkare HV, Sun S, Fansa A, Wu X, Yu B, Ma T, Wang F, Shi S. *An updated meta-analysis of Chinese herbal medicine for the prevention of COVID-19 based on Western-Eastern medicine*, Frontiers in Pharmacology, (2023) (IF: 5.6; Ranking 44/278 in PHARMACOLOGY & PHARMACY)
- 13 Luo D, Yu B, Sun S, **Chen B**, Harkare HV, Wang L, Pan J, Huang B, Song Y, Ma T, Shi S. *Effects of adjuvant berberine therapy on acute ischemic stroke: A meta-analysis*. Phytotherapy Research, (2023) (IF: 7.2; Ranking 5/60 in CHEMISTRY, MEDICINAL)
- 14 Cheung AH, Wong KY, Chiang CH, Liu X, Zhang Y, Hui CH, **Chen B**, Wang Y, Chow C, Kang W, To KF. *Interpretation of Lung Cancer Plasma EGFR Mutation Tests in the Clinical Setting*. American Journal of Clinical Pathology, (2023) (IF: 3.5; Ranking 25/76 in PATHOLOGY)
- 15 Cheung AH, Wong KY, Liu X, Ji F, Hui CH, Zhang Y, Kwan JS, **Chen B**, Dong Y, Lung RW, Yu J, Lo KW, Wong CC, Kang W, To KF. *MLK4 promotes glucose metabolism in lung adenocarcinoma through CREB-mediated activation of phosphoenolpyruvate carboxykinase and is regulated by KLF5*. Oncogenesis, (2023) (IF: 6.2; Ranking 54/241 in ONCOLOGY)

- 16 Chen G, Luo D, Qi X, Li D, Zheng J, Luo Y, Zhang C, Ren Q, Lu Y, Chan YT, **Chen B**, Wu J, Wang N, Feng Y. *Characterization of cuproptosis in gastric cancer and relationship with clinical and drug reactions*. *Frontiers in Cell and Developmental Biology*, (2023). (IF: 5.5; Ranking 5/39 in DEVELOPMENTAL BIOLOGY)
- 17 Shi S, Huang D, Wu Y, Pei C, Wang Y, Shen Z, Zhao S, Jia N, Wang X, **Chen B**, Pan J, Wang F, Wang Z. *Salidroside pretreatment alleviates PM_{2.5} caused lung injury via inhibition of apoptosis and pyroptosis through regulating NLRP3 Inflammasome*. *Food and Chemical Toxicology*, (2023). (IF: 4.3; Ranking 20/94 in TOXICOLOGY)
- 18 Shin WS, Xie F, **Chen B**, Yu P, Yu J, To KF, Kang W. *Updated Epidemiology of Gastric Cancer in Asia: Decreased Incidence but Still a Big Challenge*. *Cancers (Basel)*, (2023). (IF: 5.2; Ranking 72/241 in ONCOLOGY)
- 19 Xie F, Xie M, Yang Y, Ao W, Zhao T, Liu N, **Chen B**, Kang W, Xiao W, Gu J, *Pathway network-based quantitative modeling of the time-dependent and dose-response anti-inflammatory effect of Reduning Injection*. *Journal of Ethnopharmacology*, 307 (2023): 116216 (IF: 5.4; Ranking 4/28 in INTEGRATIVE & COMPLEMENTARY MEDICINE)
- 20 Shin WS, Xie F, **Chen B**, Yu J, Lo KW, Tse GMK, To KF, Kang W. *Exploring the Microbiome in Gastric Cancer: Assessing Potential Implications and Contextualizing Microorganisms beyond H. pylori and Epstein-Barr Virus*. *Cancers (Basel)*, (2023). (IF: 5.2; Ranking 72/241 in ONCOLOGY)

2022

- 21 **Chen B**, Song Y, Zhan Y, Zhou S, Ke J, Ao W, Zhang Y, Liang Q, He M, Li S, Xie F, Huang H, Chan WN, Cheung AHK, Ma BBY, Kang W, To KF, Xiao J, *Fangchinoline inhibits non-small cell lung cancer metastasis by reversing epithelial-mesenchymal transition and suppressing the cytosolic ROS-related Akt-mTOR signaling pathway*, *Cancer Letters*, 543 (2022) 215783 (IF: 9.7; Ranking 34/241 in ONCOLOGY)
- 22 Zhang J, **Chen B (co-first)**, Li H, Wang Y, Liu X, Wong KY, Chan WN, Chan AK, Cheung AH, Leung KT, Dong Y, Pan Y, Ke H, Liang L, Zhou Z, Xiao J, Wong CC, Wu WK, Cheng AS, Ma BB, Yu J, Lo KW, Kang W, Ka Fai To, *Cancer-associated fibroblasts potentiate colorectal cancer progression by crosstalk of the IGF2-IGF1R and Hippo-YAP1 signaling pathways*, *Journal of Pathology*, (2022) (IF: 7.3; Ranking 45/241 in ONCOLOGY)
- 23 Mui CW, Chan WN, **Chen B (co-first)**, Cheung AH, Yu J, Lo KW, Ke H, Kang W, To KF., *Targeting YAP1/TAZ in non-small-cell lung carcinoma: From molecular mechanisms to precision medicine*, *International Journal of Cancer*, (2022) (IF: 6.4; Ranking 52/241 in ONCOLOGY)
- 24 Cheung AH, Hui CH, Wong KY, Liu X, **Chen B**, Kang W, To KF., *Out of the cycle: Impact of cell cycle aberrations on cancer metabolism and metastasis*, *International Journal of Cancer*, (2022) (IF:6.4; Ranking 25/76 in ONCOLOGY)
- 25 Shi S, Wang F, **Chen B**, Pan J, Luo D, Pei C, Huang D, Wang X, Wang Y, Shen Z, Li W, Wu Y, He Y, Wang Z.ng Z. *Efficacy and Safety of Shenfu Injection for Severe Pneumonia in the Elderly: A Systematic Review and Meta-Analysis Based on Western and Eastern Medicine*, *Frontiers in Pharmacology*, 13 (2022) 779942 (IF: 5.6; Ranking 45/277 in PHARMACOLOGY & PHARMACY)
- 26 Shi S, Wang F, Huang Y, **Chen B**, Pei C, Huang D, Wang X, Wang Y, Kou S, Li W, Ma T, Wu Y, Wang Z, *Epimedium for Osteoporosis Based on Western and Eastern Medicine: An Updated Systematic Review and Meta-Analysis*, *Frontiers in Pharmacology*, 13 (2022) 782096 (IF: 5.6; Ranking 45/277 in PHARMACOLOGY & PHARMACY)
- 27 Wong KY, Cheung AH, **Chen B**, Chan WN, Yu J, Lo KW, Kang W, To KF., *Cancer-associated fibroblasts in non-small cell lung cancer: From molecular mechanisms to clinical implications*, *International Journal of Cancer*, 151

(2022) 1195-1215 (IF: 6.4; Ranking 52/241 in ONCOLOGY)

- 28 Zhan Y, Chen Q, Song Y, Wei X, Zhao T, **Chen B**, Li C, Zhang W, Jiang Y, Tan Y, Du B, Xiao J, Wang K. *Berberamine Hydrochloride inhibits lysosomal acidification by activating Nox2 to potentiate chemotherapy-induced apoptosis via the ROS-MAPK pathway in human lung carcinoma cells*, Cell Biology and Toxicology, (2022) (IF: 6.1; Ranking 58/191 in CELL BIOLOGY)
- 29 Liu X, Wang Y, **Chen B**, Chan WN, Mui CW, Cheung AHK, Zhang J, Wong KY, Yu J, Kang W, To KF, *Targeting the Hippo Pathway in Gastric Cancer and Other Malignancies in the Digestive System: From Bench to Bedside*, Biomedicines, 10 (2022) 2512 (IF: 4.7; Ranking 92/285 in BIOCHEMISTRY & MOLECULAR BIOLOGY)
- 30 Wang Y, Chen H, Liu W, Yan H, Zhang Y, Cheung AHK, Zhang J, **Chen B**, Liang L, Zhou Z, Wong CC, Wu WKK, Chan MWY, Cheng ASL, Ma BBY, Yu J, Lo KW, To KF, Kang W, *MCM6 is a critical transcriptional target of YAP to promote gastric tumorigenesis and serves as a therapeutic target*, Theranostics, 12 (2022) 6509-6526 (IF:12.4; Ranking 8/136 in MEDICINE, RESEARCH & EXPERIMENTAL)

2021

- 31 **Chen B**, Chan WN, Mui CW, Liu X, Zhang J, Wang Y, Cheung AHK, Chan AKY, Chan RCK, Leung KT, Dong Y, Pan Y, Ke H, Liang L, Zhou Z, Wong CC, Wu WKK, Cheng ASL, Yu J, Lo KW, To KF, Kang W, *STK3 promotes gastric carcinogenesis by activating Ras-MAPK mediated cell cycle progression and serves as an independent prognostic biomarker*, Molecular Cancer, 20 (2021) 147 (IF: 37.3; Ranking 4/285 in BIOCHEMISTRY & MOLECULAR BIOLOGY)
- 32 Shi S, Wang F, Yao H, Kou S, Li W, **Chen B**, Wu Y, Wang X, Pei C, Huang D, Wang Y, Zhang P, He Y, Wang Z, *Oral Chinese Herbal Medicine on Immune Responses During Coronavirus Disease 2019: A Systematic Review and Meta-Analysis*, Frontiers in Medicine (Lausanne), 8 (2021) 685734 (IF: 3.9; Ranking 58/167 in MEDICINE, GENERAL & INTERNAL)

2020

- 33 Wei X, Ke J, Huang H, Zhou S, Guo A, Wang K, Zhan Y, Mai C, Ao W, Xie F, Luo R, Xiao J, Wei H, **Chen B (corresponding)**, *Screening and Identification of Potential Biomarkers for Hepatocellular Carcinoma: An Analysis of TCGA Database and Clinical Validation*, Cancer Management and Research, 12 (2020) 1991-2000 (IF: 3.3; Ranking 135/241 in ONCOLOGY)
- 34 Wang K, Zhan Y, **Chen B (co-first)**, Lu Y, Yin T, Zhou S, Zhang W, Liu X, Du B, Wei X, Xiao J., *Tubeimoside I-induced lung cancer cell death and the underlying crosstalk between lysosomes and mitochondria*, Cell Death & Disease, 11 (2020) 708 (IF: 9.0; Ranking 31/191 in CELL BIOLOGY)
- 35 Wang K, Liu X, Liu Q, Ho IH, Wei X, Yin T, Zhan Y, Zhang W, Zhang W, **Chen B**, Gu J, Tan Y, Zhang L, Chan MT, Wu WK, Du B, Xiao J, *Hederagenin potentiated cisplatin- and paclitaxel-mediated cytotoxicity by impairing autophagy in lung cancer cells*, Cell Death & Disease, 11 (2020) 611 (IF: 9.0; Ranking 31/191 in CELL BIOLOGY)

2019

- 36 **Chen B**, Zhou S, Zhan Y, Ke J, Wang K, Liang Q, Hou Y, Zhu P, Ao W, Wei X, Xiao J, *Dioscin Inhibits the Invasion and Migration of Hepatocellular Carcinoma HepG2 Cells by Reversing TGF- β 1-Induced Epithelial-Mesenchymal Transition*, Molecules, 24 (2019) (IF: 4.6; Ranking 161/315 in BIOCHEMISTRY & MOLECULAR BIOLOGY)

- 37 Wang K, **Chen B (co-first)**, Yin T, Zhan Y, Lu Y, Zhang Y, Chen J, Wu W, Zhou S, Mao W, Tan Y, Du B, Liu X, Ho HI, Xiao J, *N-Methylparoxetine Blocked Autophagic Flux and Induced Apoptosis by Activating ROS-MAPK Pathway in Non-Small Cell Lung Cancer Cells*, International Journal of Molecular Sciences, 20 (2019) (IF: 5.6; Ranking 66/285 in BIOCHEMISTRY & MOLECULAR BIOLOGY)
- 38 Wang K, Gong Q, Zhan Y, **Chen B (co-first)**, Yin T, Lu Y, Zhang Y, Wang H, Ke J, Du B, Liu X, Xiao J, *Blockage of Autophagic Flux and Induction of Mitochondria Fragmentation by Paroxetine Hydrochloride in Lung Cancer Cells Promotes Apoptosis via the ROS-MAPK Pathway*, Frontiers in Cell and Developmental Biology, 7 (2019) 397 (IF: 5.5; Ranking 5/39 in DEVELOPMENTAL BIOLOGY)
- 39 Tan Y, Du B, Zhan Y, Wang K, Wang X, **Chen B**, Wei X, Xiao J, *Antitumor effects of circ-EPHB4 in hepatocellular carcinoma via inhibition of HIF-1 α* , Molecular Carcinogenesis, 58 (2019) 875-886 (IF: 4.6; Ranking 101/315 in BIOCHEMISTRY & MOLECULAR BIOLOGY)
- 40 Wang K, Xiao J, Liu X, Jiang Z, Zhan Y, Yin T, He L, Zhang F, Xing S, **Chen B**, Li Y, Zhang F, Kuang Z, Du B, Gu J, *AICD: an integrated anti-inflammatory compounds database for drug discovery*, Scientific Reports, 9 (2019) 7737 (IF: 4.6; Ranking 22/73 in MULTIDISPLINARY SCIENCES)

2018

- 41 Zhan Y, Wang K, Li Q, Zou Y, **Chen B**, Gong Q, Ho HI, Yin T, Zhang F, Lu Y, Wu W, Zhang Y, Tan Y, Du B, Liu X, Xiao J, *The Novel Autophagy Inhibitor Alpha-Hederin Promoted Paclitaxel Cytotoxicity by Increasing Reactive Oxygen Species Accumulation in Non-Small Cell Lung Cancer Cells*, International Journal of Molecular Sciences, 19 (2018) (IF: 5.6; Ranking 66/285 in BIOCHEMISTRY & MOLECULAR BIOLOGY)

Conference abstracts and other journal publications

- 1 **Bonan Chen**, Wai Nok Chan, Huan Yan, Xiaoli Liu, Ka Fai To, Jun Yu. *Blocking CTGF alleviates peritoneal metastasis of diffuse-type gastric cancer by disrupting the interplay of cancer cells and cancer-associated fibroblasts*. United European Gastroenterology Week, 2021. **(UEG Week Presentation Award)**
- 2 **Bonan Chen**, Jinglin Zhang, Wai-Nok Chan, Chi-Chun Wong, Jun Yu, Wei Kang, Ka-Fai To. *Cancer-associated fibroblasts promote colorectal cancer progression through IGF2-IGF1R-YAP1 axis*. International Digestive Disease Forum, 2021. **(IDDF Young Investigator Award)**
- 3 **Bonan Chen**, Wei Kang. *Unveiling the mechanism of Helicobacter pylori in gastric cancer immune evasion through spatial transcriptomics of pathological samples*. United European Gastroenterology Week, 2024. **(National Scholar Award)**
- 4 Patrick Pak-Chun Wong, Zhewen Xiong, Haoran Wu, **Bonan Chen**, Ka-Fai To, Stephen Lam Chan, Wei Kang, Alfred Sze-Lok Cheng. *Single-cell landscape of cancer-associated fibroblasts in immunotherapy resistance of hepatocellular carcinoma*. International Digestive Disease Forum, 2023.

- 5 Fuda Xie, Doris Leung, **Bonan Chen**, Jun Yu, Ka Fai To, Wei Kang. *Identification of MCM10 as a key effector of YAPI signaling that promotes cancer stemness and drug resistance in gastric carcinogenesis*. International Digestive Disease Forum, 2024.

Awarded Patents

- 1 Method and system for predicting tumor metastasis recurrence based on TCGA database. National Invention Patent (China). No. ZL 2018 1 1466604.X (**First Inventor, Awarded Date: 28/02/2023**)
- 2 A composition for the treatment of lung tumours. National Invention Patent (China). No. ZL 2020 1 0100857.6 (**Fifth Inventor, Awarded Date: 18/02/2020**)
- 3 A multifunctional massage therapeutic instrument for shoulder, elbow, and wrist. National Utility Model Patent (China). No. ZL 2015 2 0809296.1 (**First Inventor, Awarded Date: 16/11/2016**)

Filed Patents

- 1 Pharmaceutical composition, preparation method, and application. National Invention Patent (China). No. 202410467757.5 (Second Inventor, Filed Date: 28/08/2024)
- 2 FOXP4 protein inhibitor, pharmaceutical composition, and application. National Invention Patent (China). No. 202410467757.5 (Second Inventor, Filed Date: 18/04/2024)
- 3 OA-modified DKK1 aptamer-based PROTAC molecule degrader of DKK1 protein. Orphan-drug designation submitted to section 526 of the Federal, Food, Drug, and Cosmetic Act (21 U.S.C. 360bb). DRU-2024-10338 (Co-Inventor, Orphan Drug Designated by FDA: 09/10/2024)

Media reports

- 1 Highlight publication “*STK3 promotes gastric carcinogenesis by activating Ras-MAPK mediated cell cycle progression and serves as an independent prognostic biomarker*” by CUHK in Touch: <https://cuhkintouch.cpr.cuhk.edu.hk/2022/06/8305/>
- 2 “CUHK develops novel molecular classification of cancer-associated fibroblasts across multiple cancers, improving understanding for more targeted treatment” by CUHK Communications and Public Relations Office: <https://www.cpr.cuhk.edu.hk/en/press/cuhk-develops-novel-molecular-classification-of-cancer-associated-fibroblasts-across-multiple-cancers-improving-understanding-for-more-targeted-treatment/>

Awards and honors

- 1 **Outstanding Students Award**, the Chinese University of Hong Kong, 2022
- 2 **First Prize**, Outstanding Graduate Student of Guangdong Province, 2020
- 3 **First Prize**, China National Scholarship, Ministry of Education of China, 2019
- 4 **First Prize**, Graduate Student Scholarship for two academic years, GZUCM, 2017-2019
- 5 **Second Prize**, "Challenge Cup" Sci. & Tech. Works Competition of Guangdong Province, 2019
- 6 **First Prize**, GZUCM Academic Papers Competition, 2015
- 7 **Excellent Award**, GZUCM Academic Papers Competition, 2014